Crystal Research Associates, LLC has issued an Executive Informational Overview® (EIO®) on HemoBioTech, Inc.
“HemoBioTech, Inc. ('HemoBioTech' or 'the Company') is a biopharmaceutical company developing innovative blood substitute technology exclusively licensed from Texas Tech University Health Services Center ('Texas Tech'). The Company’s core product, HemoTech™, is an oxygen-carrying, bovine hemoglobin-based (Hb) solution believed to perform in a manner similar to red blood cells, as well as provide erythropoietic (inducing red blood cell production) and anti-inflammatory activity. HemoTech™ was developed on the premise that free hemoglobin-based blood substitutes can no longer be considered mere 'transport vehicles' for oxygen, carbon dioxide, and nutrients. Instead, they should possess pharmacological properties that can reduce the intrinsic toxic effects of hemoglobin and help eliminate abnormal reactions associated with blood pressure reduction and the lowering of vital signs due to blood loss during hemorrhage. Other efforts to develop blood substitutes have focused not on replacements for whole blood but rather on attempts to duplicate its oxygen-carrying capacity. These development efforts are either hemoglobin-based products derived from discarded human or bovine blood, or composed of artificially produced perfluorochemicals (PFCs). Competitor first-generation blood substitute products have failed or met with limited success to date because they were developed before the recognition of intrinsic hemoglobin-based toxicity problems, such as vasoactive potency, pro-oxidant properties, and pro-inflammatory potential. Building on over 35 years of persistent research efforts within the blood substitute industry, HemoBioTech’s blood substitute technology, HemoTech™, could become a non-toxic, anti-inflammatory, and vasodilatory blood substitute with erythropoietic activity."
To read the complete report click here
To read the quarterly update click here